Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Daratumumab + Dexamethasone + Pomalidomide + Tazemetostat|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Daratumumab||Darzalex||JNJ-54767414||CD38 Antibody 18||Darzalex (Daratumumab) is a human antibody against CD38 that induces antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity against CD38-positive tumor cells (PMID: 30546360). Darzalex (Daratumumab) is FDA approved for multiple myeloma patients as a monotherapy or in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, or with bortezomib, melphalan, and prednisone, or with pomalidomide and dexamethasone, or with bortezomib, thalidomide and dexamethasone (FDA.gov).|
|Pomalidomide||Pomalyst||CC-4047||Pomalyst (pomalidomide) is a thalidomide derivative that inhibits angiogenesis and modulates immune response, potentially lead to antitumor activity (PMID: 30069630). Pomalyst (pomalidomide) is FDA approved for use in patients with Kaposi's sarcoma who failed HAART or are HIV-negative, and in combination with dexamethasone in patients with multiple myeloma who had 2 or more prior therapies (FDA.gov).|
|Tazemetostat||Tazverik||EPZ6438|E-7438|EPZ-6438||EZH2 inhibitor 19||Tazverik (tazemetostat) binds to and inhibits EZH2, resulting in decreased tri-methylation of H3K27, and potentially leading to inhibition of cell proliferation and tumor growth (PMID: 23620515). Tazverik (tazemetostat) is FDA approved for use in patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection, and in adult patients with relapsed or refractory follicular lymphoma (R/R FL) harboring an EZH2 mutation after 2 prior therapies, and in patients with R/R FL without treatment options (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05205252||Phase Ib/II||Lenalidomide + Tafasitamab-cxix + Tazemetostat Daratumumab + Dexamethasone + Pomalidomide + Tazemetostat Daratumumab and hyaluronidase-fihj + Dexamethasone + Pomalidomide + Tazemetostat Mosunetuzumab-axgb + Tazemetostat Lenalidomide + Tazemetostat Acalabrutinib + Tazemetostat||A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. (ARIA)||Withdrawn||USA||0|